Newmont Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Newmont Corporation trades at $118.71 (market cap $123.50B), while Recursion Pharmaceuticals Inc trades at $3.34 (market cap $1.81B). The key difference: Newmont Corporation is far larger — about 68.2× Recursion Pharmaceuticals Inc's market cap, and Newmont Corporation pays a 0.89% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| NEM | RXRX | |
|---|---|---|
Market Cap | $123.50B | $1.81B |
Sector | Basic Materials | Health |
52-Week High | $131.95 | $6.79 |
52-Week Low | $67.38 | $2.84 |
Enterprise Value | $120.09B | $1.33B |
Dividend Yield | 0.89% | — |
Signals from Pluang's Aura AI — not financial advice
Newmont Corporation (NEM) trades at $117.26, up 3.79% over 24 hours, near its 52-week high. The stock exhibits strong bullish technical signals and robust fundamentals, with revenue growing to $22.67 billion in 2025 and net income reaching $7.09 billion. Recent news highlights the resolution of a Nevada joint venture dispute with Barrick Mining, providing operational clarity.
The outlook for NEM remains positive, supported by strong earnings beats, a favorable analyst consensus, and rising gold prices. Key risks include gold price volatility and execution of production targets. The consensus price target of $133.00 suggests upside potential from current levels.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →